Anlotinib

CAS No. 1058156-90-3

Anlotinib( AL-3818 )

Catalog No. M10263 CAS No. 1058156-90-3

Anlotinib (AL-3818) is a novel multi-target tyrosine kinase that primarily inhibit VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Anlotinib
  • Note
    Research use only, not for human use.
  • Brief Description
    Anlotinib (AL-3818) is a novel multi-target tyrosine kinase that primarily inhibit VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret.
  • Description
    Anlotinib (AL-3818) is a novel multi-target tyrosine kinase that primarily inhibit VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret; shows antitumor activity against tumor cells carrying mutations in PDGFR α, c-Kit, Met, and epidermal growth factor receptor (EGFR).Colon Cancer Phase 2 Clinical.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    AL-3818
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR
  • Research Area
    Cancer
  • Indication
    Colon Cancer

Chemical Information

  • CAS Number
    1058156-90-3
  • Formula Weight
    407.4375
  • Molecular Formula
    C23H22FN3O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 44 mg/mL
  • SMILES
    CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC
  • Chemical Name
    Cyclopropanamine, 1-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinolinyl]oxy]methyl]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Sun Y, et al. J Hematol Oncol. 2016 Oct 4;9(1):105.
molnova catalog
related products
  • EGFR-IN-1 hydrochlor...

    EGFR-IN-1 hydrochloride is an irreversible and specific inhibitor of L858R/T790M mutant EGFR, with 100-fold selectivity over wild-type EGFR.

  • Tarlox-TKI

    Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, with antitumor activity.Tarlox-TKI inhibits NRG1 and suppresses HER2 mutants.

  • CHF5074

    CHF5074, a γ-secretase modulator, reduces Aβ42/40 secretion (IC50: 3.6/18.4 μM).